Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg

Showing results (11-20 of 399) with videos related to

Pageof 40
Sort By:
Apoptosis : an International Journal on Programmed Cell Death|June 23, 2009
Diabetes and apoptosis: liverJörn M Schattenberg, Marcus Schuchmann
Expert Opinion on Investigational Drugs|January 15, 2020
Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected?Maurice Michel, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|February 8, 2018
[Animal Naming Test - Animals as diagnostic solution?]Christian Labenz, Jörn M Schattenberg
BMC Medicine|July 5, 2019
Assessing the disease burden of non-alcoholic fatty liver disease in the real world - big data and big numbersJörn M Schattenberg, Mattias Ekstedt
Gut|August 8, 2020
NAFLD between genes and environment: what drives fibrogenesis?Angelo Armandi, Jörn M Schattenberg
Journal of Gastroenterology and Hepatology|July 17, 2013
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approachesDetlef Schuppan, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|April 9, 2016
[Expected increase of hepatocellular carcinoma by nonalcoholic fatty liver disease]Y Alt, J M Schattenberg
Zeitschrift Fur Gastroenterologie|July 8, 2024
Jörn M Schattenberg, Frank Tacke
Alimentary Pharmacology & Therapeutics|February 10, 2021
Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' replyChristian Labenz, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|December 6, 2016
[Prime time for medical therapy in NASH?]Christian Labenz, Jörn M Schattenberg
Pageof 40

Showing results (11-20 of 399) with videos related to

Sort By:
Pageof 40
Apoptosis : an International Journal on Programmed Cell Death|June 23, 2009
Diabetes and apoptosis: liverJörn M Schattenberg, Marcus Schuchmann
Expert Opinion on Investigational Drugs|January 15, 2020
Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected?Maurice Michel, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|February 8, 2018
[Animal Naming Test - Animals as diagnostic solution?]Christian Labenz, Jörn M Schattenberg
BMC Medicine|July 5, 2019
Assessing the disease burden of non-alcoholic fatty liver disease in the real world - big data and big numbersJörn M Schattenberg, Mattias Ekstedt
Gut|August 8, 2020
NAFLD between genes and environment: what drives fibrogenesis?Angelo Armandi, Jörn M Schattenberg
Journal of Gastroenterology and Hepatology|July 17, 2013
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approachesDetlef Schuppan, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|April 9, 2016
[Expected increase of hepatocellular carcinoma by nonalcoholic fatty liver disease]Y Alt, J M Schattenberg
Zeitschrift Fur Gastroenterologie|July 8, 2024
Jörn M Schattenberg, Frank Tacke
Alimentary Pharmacology & Therapeutics|February 10, 2021
Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' replyChristian Labenz, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|December 6, 2016
[Prime time for medical therapy in NASH?]Christian Labenz, Jörn M Schattenberg
Pageof 40